Strasbourg, France & Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V. (“NEC”), a wholly owned subsidiary of NEC Corporation (TSE: 6701), a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer. TG4050 is an individualized immunotherapy based on an MVA viral vector incorporating neoantigens selected using NEC’s AI-enabled prediction platform. It is currently being evaluated in patients with head and neck cancer with the aim of preventing relapse and extending disease-free survival...

French public limited company (société anonyme)with a share capital of €1,455,643,262.50Registered office : 1973, boulevard de la Défense92000 Nanterre – France552 037 806 RCS Nanterrewww.vinci.com DISCLOSUREOF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 31 MARCH 2026Total number of shares 582,257,305Theoretical number of voting rights (including treasury stock) 582,257,305Number of voting rights (excluding treasury stock) 553,674,975This disclosure is on VINCI web site www.vinci.com(section: Finance/Investors/Regulatory information/7. Monthly information concerning the total number of voting rights and shares that make up the company’s capital)Attachment2026 03 31 ddv English version

Ivry-sur-Seine – France, April 2, 2026 Regulated information INFORMATION ON THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Statement in compliance with article L. 233-8 II of the French commercial code and article 223- 16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des marchés financiers)Stock Market Euronext ParisISIN Code FR0011476928Date   Total number of shares composing the share capital of the company Total number of gross voting rights   Total number of net voting rights (*)March 31, 2026 29,682,146 29,682,146 29,107,842(*) Net = After deduction of the shares deprived of voting right In accordance with Article 9 of the Company’s Articles of Association, any physical or legal person, acting alone or in concert, who comes to hold, or ceases to hold, directly or indirectly,...

NEXITYSociété anonymeau capital de 280 648 620 eurosSiège Social : 67 rue Arago 93400 Saint-Ouen-sur-Seine444 346 795 RCS Bobigny Monthly disclosure of the total numberof voting rights and shares composing the share capital in accordance with Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés FinanciersInformation cut-off date Total numberof shares Net total number ofvoting rights31 March 2026   56,129,724   Total gross 56,129,724Net total 55,683,282* Net total = Total number of voting rights attached to the shares – shares without voting rights Saint-Ouen-sur-Seine, 2 April 2026Attachment2026_04_02 – Monthly disclosure of voting rights and shares – March 2026

 Paris, 2 April 2026, 5:45 pm    INFORMATION ON TOTAL NUMBER OF VOTING RIGHTS AND NUMBER OF SHARES PURSUANT TO ARTICLE L.233-8 II OF THE FRENCH COMMERCIAL CODE AND ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY   Date Class of shares Number of shares Number of theoretical voting rights Number of exercisable voting rights (excluding shares bought back by the Company (deprived of voting rights) and shares deprived of voting rights in accordance with art. L. 233-14 of the French Commercial Code)31 March 2026 Ordinary shares (par value of €1,25) 103,408,575 103,408,575 102,779,199  Contact  RUBIS – Legal department  Tel. : +33 (0)1 44 17 95 95AttachmentRUBIS: Information relating to the total number of voting rights and shares as of 31/03/2026

AB KN Energies (hereinafter – KN, the Company) announces the audited consolidated (hereinafter – the Group) and separate financial results for the twelve months ended 31 December 2025. Key financial indicators for the 1-12 months of 2025:EUR millions Group Company  1-12 months of 2025 1-12 months of 2024 1-12 months of 2025 1-12 months of 2024Revenue 105.2 93.7 99.9 89.4EBITDA 53.5 48.8 51.2 46.4Normalized EBITDA 47.8 46.7 45.5 44.3Net profit (loss) 18.2 15.4 16.7 13.8Normalized net profit (loss) 13.4 13.9 12.0 12.0Normalized net profit margin, % 12.8% 14.5% 12.0% 13.4%  Enclosed: AB KN Energies 2025 Management Report together with the consolidated and separate financial statements prepared in accordance with International Financial Reporting Standards as adopted by the European Union. The Management Report...

OTTAWA, ON and IQALUIT, NU, April 02, 2026 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, and Northwestel, the largest communications provider in Canada’s North, today announced that Northwestel has signed a multi-year contract for Telesat Lightspeed Low Earth Orbit (LEO) satellite services. Northwestel will leverage the advanced LEO network to deliver low latency, sovereign broadband connectivity to communities across Northern Canada. By leveraging the Government of Canada’s Telesat Lightspeed capacity pool, Northwestel plans to provide high speed broadband, offering plans with at least 50 Mbps download and 10 Mbps upload speeds and unlimited monthly usage. Today, Northwestel serves 97 communities across Canada through a combination of fibre-powered and satellite...

SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug Administration (FDA) of the CardiAMP HF clinical study data and on its plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP® System for ischemic chronic heart failure with reduced ejection fraction (HFrEF). This meeting request is in line with previous guidance and BioCardia expects to have the meeting during this quarter. The meeting will be held under BioCardia’s FDA Breakthrough Designation for the CardiAMP System. The key objectives of the meeting are to obtain FDA feedback on the acceptability of BioCardia’s proposed submission for approval...

Geneva, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “the Company”), a leading developer of semiconductors, PKI, and post-quantum technology hardware and software products, and its subsidiary IC’Alps today announced a series of significant advances in their Common Criteria (CC) security certification programs — including the successful completion of the most demanding hardware security tests for the QS7001 Secure Element platform and the unqualified renewal of IC’Alps’ site certification. Advanced Hardware Security Testing Cleared on QS7001 (CC EAL 5+) In a pivotal step toward full CC EAL 5+ certification, independent evaluator SERMA has confirmed that SEALSQ’s QS7001 Secure Element passed fault injection and side-channel attack resistance...

Bell ceremony precedes Daktronics’ 2026 Investor Day on April 9 BROOKINGS, S.D., April 02, 2026 (GLOBE NEWSWIRE) — Daktronics (NASDAQ: DAKT), the leading U.S.-based designer and manufacturer of best-in-class dynamic video communication displays and control systems for customers worldwide, today announced the company will ring the Closing Bell at the Nasdaq MarketSite in New York’s Times Square on Apr. 8, 2026. The ceremony will be led by Ramesh Jayaraman, president and CEO of Daktronics, accompanied by members of the company’s leadership team, Board of Directors, employees and other key stakeholders who have been instrumental in supporting Daktronics’ journey. “Ringing the Nasdaq Closing Bell will be an exciting milestone for our team and an important moment for our shareholders,” said Jayaraman, who began in this role on Feb. 2,...